Drawn-out battle ends with $3.3 billion takeover deal
On Tuesday Insignia, formerly known as IOOF, backed a $3.3 billion takeover from private equity firm CC Capital, bringing to a close a previous bidding war for the firm.
ASX-listed Insignia agreed to the deal at $4.80 a share, which is a premium of more than 50 per cent to its share price before private equity giant Bain Capital made a bid for Insignia last year, igniting a series of rival bids.
Bain's approach sparked a three-way contest for the business with CC Capital and Canadian giant Brookfield Capital earlier this year. Brookfield pulled out of the bidding war in March, while Bain dropped out in May, citing volatility on global markets.
CC Capital, a New York-based private equity firm, is buying Insignia with an alternative asset manager called OneIM. The deal will be CC Capital's first investment in Australia, and it is subject to approvals from Insignia shareholders and authorities including the Foreign Investment Review Board and the prudential regulator.
Loading
Insignia is the fifth-biggest player in the super sector, where it owns MLC and various other brands, and this is a key attraction for the buyer. Insignia's predecessor, IOOF, was established in 1846 as the Independent Order of Oddfellows friendly society, and it ultimately listed on the ASX in 2003.
Insignia's chief executive, Scott Hartley, said the business was well suited to being owned by CC Capital, which has a longer investment time frame than most private equity investors, giving it the ability to 'look through' market cycles. He argued this long-term horizon of CC meant it could focus strongly on members' interests.
'They understand that if you're not delivering competitive returns to members or competitive outcomes to members, whether it be returns, service, product features and structures, online capabilities, you are not going to be sustainable long-term,' he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
32 minutes ago
- News.com.au
Top 10 at 11: ASX ticks up as gold stocks extend gains; CDE brings ex-Nvidia AI expert onboard
Morning, and welcome to Stockhead's Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks off in earnest. In brief, this is what the market has been up to this morning. Gold prices lift again Spot gold climbed 1.1% overnight, hitting US$3433.5 per ounce as US bond yields continue to fall. That momentum has given the ASX a shot in the arm, up 0.35% in the first hour of trade with the materials sector up 1.95% and the All Ords Gold index climbing 2.31%. Healthcare is dragging in the other direction, down 0.64% while the ASX 200 Banks index slides lower yet again, down 0.41%. After a back-and-forth day of essentially flat trade yesterday, it'll be interesting to see whether the bulls or the bears come out on top today. WINNERS Code Name Last % Change Volume Market Cap CDE Codeifai Limited 0.026 44% 18576226 $8,494,218 GTE Great Western Exp. 0.015 36% 2155603 $6,245,337 FAU First Au Ltd 0.005 25% 3855928 $8,305,165 1CG One Click Group Ltd 0.011 22% 3614212 $10,640,575 ALY Alchemy Resource Ltd 0.006 20% 667502 $5,890,381 AUR Auris Minerals Ltd 0.006 20% 84033 $2,383,130 AON Apollo Minerals Ltd 0.007 17% 72800 $5,570,741 ATS Australis Oil & Gas 0.008 14% 6353533 $9,226,437 DTM Dart Mining NL 0.004 14% 2968000 $4,193,195 ICR Intelicare Holdings 0.016 14% 62500 $6,806,634 In the news... Codeifai (ASX:CDE) has brought ex-Nvidia AI and machine learning expert Rafael Possas onto its strategic advisory panel as the company completes acquisition of to be redubbed as the QuantumAI Secure platform. The secured payment platform is AI-driven and quantum-secured, safeguarding payments, file transfers and end-to-end communications. First AU (ASX:FAU) has initiated a 3000m drilling program at the Nimba gold project after an extensive surface mapping program over a 10 square kilometre area. FAU is looking for a potential ore body, delving into the local geological system in the search for fresh gold mineralisation. Life admin company One Click Group (ASX:1CG) has exceeded its 2024 July revenue numbers in just 18 days this year, pulling in $2.2m in revenue in just over two weeks. The company's returning customer lodgement rate also increased, rising to 72% compared to 63% the previous year. LAGGARDS Code Name Last % Change Volume Market Cap EEL Enrg Elements Ltd 0.001 -50% 385807 $6,507,557 RLG Roolife Group Ltd 0.003 -25% 19000 $6,371,125 CLA Celsius Resource Ltd 0.006 -14% 1390 $21,948,419 IPB IPB Petroleum Ltd 0.006 -14% 10000 $4,944,821 SPX Spenda Limited 0.006 -14% 515855 $32,306,508 TG1 Techgen Metals Ltd 0.021 -13% 225395 $3,807,977 ANO Advance Zinctek Ltd 0.97 -12% 2000 $68,910,718 HMI Hiremii 0.048 -11% 20000 $7,944,231 KGD Kula Gold Limited 0.008 -11% 1445684 $8,291,283 IND Industrialminerals 0.135 -10% 13465 $12,048,375
News.com.au
6 hours ago
- News.com.au
Biocurious: The cannabis stocks that stand out in a field of weeds
Cannabis suppliers are struggling to differentiate themselves in a commoditised market Regulators have lax telehealth prescribers in their sights Althea Group has sold its medical pot arm in favour of THC-infused beverages Having sprouted in a field of hope and hype eleven years ago, the ASX medicinal cannabis sector has wilted in the face of unrealistic expectations and misguided strategies. Demand isn't the problem: patients have embraced medical weed zealously since it was legalised a decade ago. Globally, most western countries have sanctioned both medical usage and many have condoned recreational indulgence (including most US states). Because there's only two approved cannabis treatments, local dispensing is largely carried out via an authorised prescriber scheme. In the six months to December 2024, these docs wrote 377,840 prescriptions. Of these, 230,091 were for products with a THC content of more than 98%. Patients aren't mucking around. What's not to like? The answer is rampant oversupply of the green stuff coupled with the rise of telehealth clinics, some of which are being criticised for alleged 'tick and flick' dispensing practices. Echoing Australian Medical Association concerns, Little Green Pharma (ASX:LGP) CEO Paul Long refers to 'poor actors' in the local market. 'Reports constantly refer to a handful of doctors, often junior doctors that are either being coerced, or paid exorbitant money to write a huge volume of THC scripts,' he says. 'I agree it is an issue and calling it out for the long-term growth of our industry is important." He adds hundreds of thousands have tried medical cannabis when nothing has worked, with great success. Reflecting the 'commoditised' market, Althea Group (ASX:AGH) in May sold its local medical cannabis business, Tasmanian Botanics Pty Ltd for a knock-down $1 million. 'The market has become irrational,' says Althea CEO Joshua Fegan. 'It's very saturated, with product from places like Canada, South Africa and Colombia'. He says most of the consumption is by way of dried flower, which implies folk might be smoking the devil's lettuce for jollies rather than using it medicinally. We'll delve further into Althea's new direction below. The dope on how to get it right While most suppliers have withered, a handful prosper via differentiated strategies and perhaps a bit of luck. They are producing meaningful revenues and – in some cases - profits. The Perth-based Little Green Pharma derives 80% of its revenue from the local market, but its greater fortunes align to the rapidly evolving European market. Germany is in the throes of partial legalisation. In France, the company supplies a pilot program that's a precursor to legalisation. Little Green's owns a production facility in Denmark – Europe's biggest – purchased from Canada's Canopy Growth for a knock-down $20 million three years ago. Two hours from the German border, the facility provides a streamlined route to the biggest Continental markets. 'It's very unlikely a site like this will be built again in the foreseeable future,' Little Green CEO Paul Long says. Meanwhile, the company's Busselton facility becomes a 'craft' producer of a small amount of slowly cured, hand trimmed, genetically superior stuff. Naturally, this attracts a better margin. In the year to March 2025 Little Green grew its revenue by 43%, to a record $36.8 million 'against a backdrop of significant regulatory change and intense competition'. European revenues doubled. Adjusted for non-cash items, Little Green managed underlying earnings of $2.9 million compared with a previous $1.6 million loss. From gummies to suppositories Bioxyne (ASX:BXN) has a modest $64 million market cap, but that's big enough to confer 'sector leader' status. Bioxyne's engine room is Breathe Life Sciences (BLS), acquired via scrip in 2023. BLS makes and distributes medical cannabis and other consumer health products, either under its own brands or third-party labels. (locally, Bioxyne is also the only licensed maker of MDMA and psilocybin for authorised prescribers and pyschedelic clinical trials). In 2019 the company launched in the UK and Japan via its well-known Dr Watson brand, covering everything from gummies, to vapes to suppositories. BLS too has entered the German market with a deal to supply a minimum 1.6 tonnes of cannabis flower and finished product to two clients. The company expects the agreement will reap a minimum of $5.6 million of revenue in the 2025-26 year. Ja, das ist gut! Bioxyne CEO Sam Watson expects German demand to rapidly overtake the $1 billion a year Australian market. On June 12 the company upgraded full-revenue expectations from $25 million to $28 million, a lofty step up from the previous year's $9.65 million. The Ebay of medicinal dope Formerly known as Cronos Australia, Vitura Health (ASX:VIT) doesn't produce any of its own material, but operates a marketplace that sells hundreds of flowers and oils from third party suppliers. Vitura also has expanded into prescription nicotine vapes. The company has built a network of physical and online prescribers, mainly via acquisition. Vitura owns the Canview marketplace, Doctors on Demand telehealth business, CDA Clinics (medical cannabis telehealth) and the clinic chain Candor Medical. In May, Vitura's 50% joint venture Flora acquired the digital platform Heyday Medical, 'one of Australia's most respected medicinal cannabis clinics'. Established in 2020, the chain claims to have serviced more than more than 5000 patients. Last November Flora acquired the Releaf Group, which operates telehealth and physical clinics. In a March quarter update, Vitura said full-year revenue was unlikely to meet the targeted 10% improvement. But the June quarter implies a yearly run rate of $138 million, up 11%. Management also expects a 20% improvement on last year's normalised underlying earnings of $8.4 million. Putting the pep into soft drinks Coming back to Althea, the company's new schtick is entering the North American market for THC-infused beverages. (THC is the psychoactive component of cannabis). Yep, these bevvies are legal in Canada and the US and are sold in bottle shops alongside alcohol. Althea's foray is by way of its subsidiary Peak. Althea's Fegan says when Peak started producing in 2021, only 4% of cannabis consumers had tried these drinks. Now, the number is more like one-quarter of them. He says the drinks have a similar effect to a similar sized serve of alcohol, but without the hangover. 'It ticks a lot of boxes as a good consumer product,' he says. Peak's competitive edge is its technique to produce the THC emulsion, without the 'planty' taste of dope. Peak's offerings include seltzers, sodas and mocktails – but it's not yet putting the 'pep' into Pepsi. Peak Canada has just launched its own brand Snap Back, a heady mix of THC and rosin (pine resin). By December Althea expects to have four or five US production sites, as close to distributors as possible. 'These big alcohol companies are looking closely at this space and our job is to develop drinks for those type of companies and produce them at scale," Fegan says. In the December half, Althea derived $8.2 million of revenue in Canada and the company expects this to grow during the summer months. Given the sale of its Australian business, Althea in May withdrew its full-year guidance of revenue between $26-33 million and underlying earnings of $800,000 to $1.1 million. Althea lost $2.6 million in the March quarter. But Fegan says the company should be cash flow positive without the drag of the divested Australian business.
Sydney Morning Herald
7 hours ago
- Sydney Morning Herald
ASX set to rise, Wall Street mixed; Trump labels Fed chief a ‘numbskull'
Wall Street is hanging around its records following some mixed profit reports, as General Motors and other big US companies give updates on how much President Donald Trump's tariffs are hurting or helping them. The S&P 500 was 0.1 per cent higher in late trading and on track to squeak to another all-time high. The Dow Jones was up 164 points, or 0.4 per cent, in late trade, and the Nasdaq composite was down 0.2 per cent after setting its own record. The Australian sharemarket is set to rise, with futures pointing to a gain of 40 points, or 0.5 per cent, at the open. The ASX edged 0.1 per cent higher on Tuesday. General Motors dropped 7.5 per cent despite reporting a stronger profit for the spring than analysts expected. The automaker said it's still expecting a $US4 billion-$US5 billion ($6.1 billion- $7.6 billion) hit to its results over 2025 because of tariffs and that it hopes to mitigate 30 per cent of that. GM also said it will feel more pain because of tariffs in the current quarter than it did during the spring. Loading That helped to offset big gains for some homebuilders after they reported stronger profits for the spring than Wall Street had forecast. D.R. Horton rallied 16.5 per cent, and PulteGroup jumped 11.4 per cent. That was even as both companies said homebuyers are continuing to deal with challenging conditions, including higher mortgage rates and an uncertain economy. So far, the US economy seems to be powering through all the uncertainty created by Trump's on-and-off tariffs. Many of Trump's stiff proposed taxes on imports are currently on pause, and the next big deadline is Aug. 1. Talks are underway on possible trade deals with other countries that could lower the proposed tariffs before they kick in. Companies are already feeling effects. Genuine Parts, the Atlanta-based company that sells auto and industrial replacement parts around the world, trimmed its profit forecast for the full year in order to incorporate 'all US tariffs currently in effect,' along with its updated expectations for business conditions in the second half of the year. Its stock rose 6.5 per cent after it reported a stronger profit for the latest quarter than analysts expected.
